3 Firms Shape Pfizer's $5.4B Deal For Sickle Cell-Drug Maker
Pfizer Inc. will acquire sickle cell-drug company Global Blood Therapeutics in a $5.4 billion enterprise value deal shaped by legal advisers Cravath Swaine & Moore LLP, Goodwin Procter LLP and Wachtell...To view the full article, register now.
Already a subscriber? Click here to view full article